Pathway landscapes and epigenetic regulation in breast cancer and melanoma cell lines

Theoretical Biology and Medical Modelling

Volumn 11, Issue SUPPL.1, 2014, Pages

  El Baroudi, Mariama ^a   La Sala, Dario ^b   Cinti, Caterina ^c   Capobianco, Enrico ^a,d  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Demethylation; Pathway Landscapes; Regulatory Networks

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE;

ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DOWN REGULATION; DRUG EFFECTS; FEMALE; GENE REGULATORY NETWORK; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MELANOMA; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GENE; UPREGULATION;

AZACITIDINE; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE REGULATORY NETWORKS; GENES, NEOPLASM; HUMANS; MELANOMA; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84900298925     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-11-S1-S8     Document Type: Article

References (81)

1. Epigenetics in cancer. Sharma S, Kelly TK, Jones PA, Carcinogenesis 2010 31 27 36 10.1093/carcin/bgp220 19752007
2. Epigenetics in cancer: what's the future? Boumber Y, Issa J-PJ, Oncol Williston Park N 2011 25 220 226 228 21548464
3. Epigenetic therapy of cancer: past, present and future. Yoo CB, Jones PA, Nat Rev Drug Discov 2006 5 37 50 10.1038/nrd1930 16485345
4. Epigenetic changes in cancer. Grønbaek K, Hother C, Jones PA, Apmis Acta Pathol Microbiol Immunol Scand 2007 115 1039 1059 10.1111/j.1600-0463.2007.apm-636.xml.x 18042143
5. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Momparler RL, Semin Oncol 2005 32 443 451 10.1053/j.seminoncol.2005.07.008 16210084
6. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia. Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL, Anticancer Drugs 2005 16 301 308 10.1097/00001813-200503000-00009 15711182
7. DNA methylation and cancer. Momparler RL, Bovenzi V, J Cell Physiol 2000 183 145 154 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V 10737890
8. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE, Cancer 2010 116 4043 4053 10.1002/cncr.25204 20564122
9. Expression profiling after induction of demethylation in MCF-7 breast cancer cells identifies involvement of TNF-α mediated cancer pathways. Kim JH, Kang S, Kim TW, Yin L, Liu R, Kim SJ, Mol Cells 2012 33 127 133 10.1007/s10059-012-2182-8 22228181
10. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, Lin Y, Christner S, Kirkwood JM, Ann Oncol Off J Eur Soc Med Oncol Esmo 2013 24 1112 1119 10.1093/annonc/mds591 23172636
11. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Måsbäck A, Westerdahl J, Olsson H, Ingvar C, J Natl Cancer Inst 2000 92 1260 1266 10.1093/jnci/92.15.1260 10922411
12. XPD common variants and their association with melanoma and breast cancer risk. Debniak T, Scott RJ, Huzarski T, Byrski T, Masojć B, van de Wetering T, Serrano-Fernandez P, Górski B, Cybulski C, Gronwald J, Debniak B, Maleszka R, Kładny J, Bieniek A, Nagay L, Haus O, Grzybowska E, Wandzel P, Niepsuj S, Narod SA, Lubinski J, Breast Cancer Res Treat 2006 98 209 215 10.1007/s10549-005-9151-2 16685590
13. MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk. Debniak T, Scott R, Masojc B, Serrano-Fernández P, Huzarski T, Byrski T, Debniak B, Górski B, Cybulski C, Medrek K, Kurzawski G, van de Wetering T, Maleszka R, Kładny J, Lubinski J, Int J Cancer J Int Cancer 2006 119 2597 2602 10.1002/ijc.22210 16988943
14. Association between female breast cancer and cutaneous melanoma. Goggins W, Gao W, Tsao H, Int J Cancer J Int Cancer 2004 111 792 794 10.1002/ijc.20322 15252852
15. Antiestrogen therapy for breast cancer modifies the risk of subsequent cutaneous melanoma. Huber C, Bouchardy C, Schaffar R, Neyroud-Caspar I, Vlastos G, Le Gal F-A, Rapiti E, Benhamou S, Cancer Prev Res Phila Pa 2012 5 82 88 10.1158/1940-6207.CAPR-11-0332 21933913
16. Human breast and melanoma cancer stem cells biomarkers. La Porta CAM, Zapperi S, Cancer Lett 2012 22445909
17. Extracting consistent knowledge from highly inconsistent cancer gene data sources. Gong X, Wu R, Zhang Y, Zhao W, Cheng L, Gu Y, Zhang L, Wang J, Zhu J, Guo Z, BMC Bioinformatics 2010 11 76 10.1186/1471-2105-11-76 20137077
18. The ConsensusPathDB interaction database: 2013 update. Kamburov A, Stelzl U, Lehrach H, Herwig R, Nucleic Acids Res 2013 41 Database 793 800 23143270
19. Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Essaghir A, Toffalini F, Knoops L, Kallin A, van Helden J, Demoulin J-B, Nucleic Acids Res 2010 38 120 10.1093/nar/gkq149 20215436
20. miRTarBase: a database curates experimentally validated microRNA-target interactions. Hsu S-D, Lin F-M, Wu W-Y, Liang C, Huang W-C, Chan W-L, Tsai W-T, Chen G-Z, Lee C-J, Chiu C-M, Chien C-H, Wu M-C, Huang C-Y, Tsou A-P, Huang H-D, Nucleic Acids Res 2011 39 Database 163 169 10.1093/nar/gkq1107 21071411
21. miRecords: an integrated resource for microRNA-target interactions. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T, Nucleic Acids Res 2009 37 Database 105 110 10.1093/nar/gkn851 18996891
22. miR2Disease: a manually curated database for microRNA deregulation in human disease. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G, Liu Y, Nucleic Acids Res 2009 37 Database 98 104 10.1093/nar/gkn714 18927107
23. Cytoscape 2.8: new features for data integration and network visualization. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T, Bioinforma Oxf Engl 2011 27 431 432 10.1093/bioinformatics/btq675 21149340
24. An improved method for genome wide DNA methylation profiling correlated to transcription and genomic instability in two breast cancer cell lines. Li J, Gao F, Li N, Li S, Yin G, Tian G, Jia S, Wang K, Zhang X, Yang H, Nielsen AL, Bolund L, Bmc Genomics 2009 10 223 10.1186/1471-2164-10-223 19439076
25. Cancer/testis (CT) antigens: potential targets for immunotherapy. Caballero OL, Chen Y-T, Cancer Sci 2009 100 2014 2021 10.1111/j.1349-7006.2009. 01303.x 19719775
26. Cancer/testis antigens, gametogenesis and cancer. Simpson AJG, Caballero OL, Jungbluth A, Chen Y-T, Old LJ, Nat Rev Cancer 2005 5 615 625 10.1038/nrc1669 16034368
27. NY-ESO-1: review of an immunogenic tumor antigen. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen Y-T, Old LJ, Adv Cancer Res 2006 95 1 30 16860654
28. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Nishikawa H, Maeda Y, Ishida T, Gnjatic S, Sato E, Mori F, Sugiyama D, Ito A, Fukumori Y, Utsunomiya A, Inagaki H, Old LJ, Ueda R, Sakaguchi S, Blood 2012 119 3097 3104 10.1182/blood-2011-09-379982 22323448
29. Role of Rab GTPases in membrane traffic and cell physiology. Hutagalung AH, Novick PJ, Physiol Rev 2011 91 119 149 10.1152/physrev.00059.2009 21248164
30. Rab30 is required for the morphological integrity of the Golgi apparatus. Kelly EE, Giordano F, Horgan CP, Jollivet F, Raposo G, McCaffrey MW, Biol Cell Auspices Eur Cell Biol Organ 2012 104 84 101 22188167
31. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma. Errington JA, Conway RM, Walsh-Conway N, Browning J, Freyer C, Cebon J, Madigan MC, Br J Ophthalmol 2012 96 451 458 10.1136/bjophthalmol-2011-300432 22190731
32. Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells. Putnik M, Zhao C, Gustafsson J-Å Dahlman-Wright K, Biochem Biophys Res Commun 2012 426 26 32 10.1016/j.bbrc.2012.08.007 22902638
33. FHL2 inhibits the Id3-promoted proliferation and invasive growth of human MCF-7 breast cancer cells. Chen Y-H, Wu Z-Q, Zhao Y-L, Si Y-L, Guo M-Z, Han W-D, Chin Med J (Engl) 2012 125 2329 2333 22882857
34. Regulation of S100A2 expression by TGF-β-induced MEK/ERK signalling and its role in cell migration/invasion. Naz S, Ranganathan P, Bodapati P, Shastry AH, Mishra LN, Kondaiah P, Biochem J 2012 447 81 91 10.1042/BJ20120014 22747445
35. Correlation between epigenetic alterations in the insulin growth factor-II gene and hepatocellular carcinoma. Dong Z, Yao D, Wu W, Qiu L, Yao N, Yan X, Yu D, Chen J, Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin J Hepatol 2012 20 593 597 23207153
36. Regulation of Rev1 by the Fanconi anemia core complex. Kim H, Yang K, Dejsuphong D, D'Andrea AD, Nat Struct Mol Biol 2012 19 164 170 10.1038/nsmb.2222 22266823
37. The regulation of INK4/ARF in cancer and aging. Kim WY, Sharpless NE, Cell 2006 127 265 275 10.1016/j.cell.2006.10.003 17055429
38. TGF-β-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex. Thillainadesan G, Chitilian JM, Isovic M, Ablack JNG, Mymryk JS, Tini M, Torchia J, Mol Cell 2012 46 636 649 10.1016/j.molcel.2012.03.027 22560925
39. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Haaf T, Pharmacol Ther 1995 65 19 46 10.1016/0163-7258(94)00053-6 7536332
40. Expression profile of N-cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma. Shimazui T, Kojima T, Onozawa M, Suzuki M, Asano T, Akaza H, Oncol Rep 2006 15 1181 1184 16596183
41. Cadherin-7 interacts with melanoma inhibitory activity protein and negatively modulates melanoma cell migration. Winklmeier A, Contreras-Shannon V, Arndt S, Melle C, Bosserhoff A-K, Cancer Sci 2009 100 261 268 10.1111/j.1349-7006.2008.01048.x 19200257
42. Extracellular fragment of brain-specific angiogenesis inhibitor 1 suppresses endothelial cell proliferation by blocking alphavbeta5 integrin. Koh JT, Kook H, Kee HJ, Seo Y-W, Jeong BC, Lee JH, Kim M-Y, Yoon KC, Jung S, Kim KK, Exp Cell Res 2004 294 172 184 10.1016/j.yexcr.2003.11.008 14980512
43. Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts. Rao-Bindal K, Rao CK, Yu L, Kleinerman ES, Pediatr Blood Cancer 2013 60 575 579 10.1002/pbc.24412 23255321
44. Down-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells. Wang Q, Sun W, Hao X, Li T, Su L, Liu X, Cancer Cell Int 2012 12 54 10.1186/1475-2867-12-54 23256568
45. Phosphorylation of Daxx by ATM contributes to DNA damage-induced p53 activation. Tang J, Agrawal T, Cheng Q, Qu L, Brewer MD, Chen J, Yang X, Plos One 2013 8 55813 10.1371/journal.pone.0055813 23405218
46. Anti-adipogenic effect of PDGF is reversed by PKC inhibition. Artemenko Y, Gagnon A, Aubin D, Sorisky A, J Cell Physiol 2005 204 646 653 10.1002/jcp.20314 15754337
47. p63 and p73: roles in development and tumor formation. Moll UM, Slade N, Mol Cancer Res Mcr 2004 2 371 386 15280445
48. Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs-pRb2/p130 complexes. La Sala D, Macaluso M, Trimarchi C, Giordano A, Cinti C, Oncogene 2003 22 3518 3529 10.1038/sj.onc.1206487 12789260
49. Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis. Zhao Y, Fei C, Zhang X, Zhang Y, Guo J, Gu S, Li X, Chang C, Tumour Biol J Int Soc Oncodevelopmental Biol Med 2013 34 165 172 10.1007/s13277-012-0524-y 23055192
50. p73 induces apoptosis by different mechanisms. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, Krammer PH, Melino G, Candi E, Biochem Biophys Res Commun 2005 331 713 717 10.1016/j.bbrc.2005.03.156 15865927
51. Excision of 5-hydroxymethyluracil and 5-carboxylcytosine by the thymine DNA glycosylase domain: its structural basis and implications for active DNA demethylation. Hashimoto H, Hong S, Bhagwat AS, Zhang X, Cheng X, Nucleic Acids Res 2012 40 10203 10214 10.1093/nar/gks845 22962365
52. A population-based study of DNA repair gene variants in relation to non-melanoma skin cancer as a marker of a cancer-prone phenotype. Ruczinski I, Jorgensen TJ, Shugart YY, Schaad YB, Kessing B, Hoffman-Bolton J, Helzlsouer KJ, Kao WHL, Wheless L, Francis L, Alani RM, Strickland PT, Smith MW, Alberg AJ, Carcinogenesis 2012 33 1692 1698 10.1093/carcin/bgs170 22581838
53. Cancer-associated variants and a common polymorphism of MUTYH exhibit reduced repair of oxidative DNA damage using a GFP-based assay in mammalian cells. Raetz AG, Xie Y, Kundu S, Brinkmeyer MK, Chang C, David SS, Carcinogenesis 2012 33 2301 2309 10.1093/carcin/bgs270 22926731
54. Expression of retinoic acid-related orphan receptor alpha and its responsive genes in human endometrium regulated by cholesterol sulfate. Zenri F, Hiroi H, Momoeda M, Tsutsumi R, Hosokawa Y, Koizumi M, Nakae H, Osuga Y, Yano T, Taketani Y, J Steroid Biochem Mol Biol 2012 128 21 28 10.1016/j.jsbmb.2011. 10.001 22024429
55. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, Bulavin DV, Oncogene 2007 26 2502 2506 10.1038/sj.onc.1210032 17016428
56. Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Hurwitz J, Hayashi Y, Cancer Sci 2011 102 1101 1106 10.1111/j.1349-7006.2011.01898.x 21281403
57. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Lu X, Nguyen T-A, Moon S-H, Darlington Y, Sommer M, Donehower LA, Cancer Metastasis Rev 2008 27 123 135 10.1007/s10555-008-9127-x 18265945
58. [Monitoring of patients with cardiac transplantation]. Cabrol A, Desruennes M, Léger P, Ann Cardiol Angéiologie 1990 39 607 612
59. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas. Kondratiev S, Gnepp DR, Yakirevich E, Sabo E, Annino DJ, Rebeiz E, Laver NV, Hum Pathol 2008 39 337 343 10.1016/j.humpath.2007.07.003 18045645
60. Matrix metalloproteinases: regulators of the tumor microenvironment. Kessenbrock K, Plaks V, Werb Z, Cell 2010 141 52 67 10.1016/j.cell.2010.03.015 20371345
61. AP-1: a double-edged sword in tumorigenesis. Eferl R, Wagner EF, Nat Rev Cancer 2003 3 859 868 10.1038/nrc1209 14668816
62. Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems. Ma Y, Li Q, Cui W, Miao N, Liu X, Zhang W, Zhang C, Wang J, Diagn Pathol 2012 7 120 10.1186/1746-1596-7-120 22974165
63. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM, Proc Natl Acad Sci USA 2002 99 15524 15529 10.1073/pnas.242606799 12434020
64. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR, Johnson JM, Cummins JM, Raymond CK, Dai H, Chau N, Cleary M, Jackson AL, Carleton M, Lim L, Mol Cell Biol 2007 27 2240 2252 10.1128/MCB.02005-06 17242205
65. MiR-155 negatively regulates c-Jun expression at the post-transcriptional level in human dermal fibroblasts in vitro: implications in UVA irradiation-induced photoaging. Song J, Liu P, Yang Z, Li L, Su H, Lu N, Peng Z, Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 2012 29 331 340 10.1159/000338488 22508041
66. Oleuropein induces anti-metastatic effects in breast cancer. Hassan ZK, Elamin MH, Daghestani MH, Omer SA, Al-Olayan EM, Elobeid MA, Virk P, Mohammed OB, Asian Pac J Cancer Prev Apjcp 2012 13 4555 4559 10.7314/APJCP.2012.13.9.4555 23167379
67. NADPH quinone oxidoreductase 1 mediates breast cancer cell resistance to thymoquinone-induced apoptosis. Sutton KM, Doucette CD, Hoskin DW, Biochem Biophys Res Commun 2012 426 421 426 10.1016/j.bbrc.2012.08.111 22960073
68. Suppression of the invasion and migration of cancer cells by SERPINB family genes and their derived peptides. Chou R-H, Wen H-C, Liang W-G, Lin S-C, Yuan H-W, Wu C-W, Chang W-SW, Oncol Rep 2012 27 238 245 21993616
69. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Evans MK, Yu C-R, Lohani A, Mahdi RM, Liu X, Trzeciak AR, Egwuagu CE, Oncogene 2007 26 1941 1948 10.1038/sj.onc.1209993 17001312
70. Aberrant amplification of the crosstalk between canonical Wnt signaling and N-glycosylation gene DPAGT1 promotes oral cancer. Jamal B, Sengupta PK, Gao Z-N, Nita-Lazar M, Amin B, Jalisi S, Bouchie MP, Kukuruzinska MA, Oral Oncol 2012 48 523 529 10.1016/j.oraloncology.2012.01.010 22341307
71. Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M, Breast Cancer Res Bcr 2004 6 1 7 10.1186/bcr730 14680494
72. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen S-S, Blagitko-Dorfs N, Maharry K, Whitman SP, Schmittgen TD, Lübbert M, Marcucci G, Bloomfield CD, Plass C, Cancer Res 2008 68 3142 3151 10.1158/0008-5472.CAN-08-0483 18451139
73. MicroRNA hsa-miR-138 inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells through adenovirus EID-1. Yang Z, Bian C, Zhou H, Huang S, Wang S, Liao L, Zhao RC, Stem Cells Dev 2011 20 259 267 10.1089/scd.2010.0072 20486779
74. Cyclooxygenases: structural, cellular, and molecular biology. Smith WL, DeWitt DL, Garavito RM, Annu Rev Biochem 2000 69 145 182 10.1146/annurev. biochem.69.1.145 10966456
75. Cyclooxygenase-2 as a target for anticancer drug development. Méric J-B, Rottey S, Olaussen K, Soria J-C, Khayat D, Rixe O, Spano J-P, Crit Rev Oncol Hematol 2006 59 51 64 10.1016/j.critrevonc.2006.01.003 16531064
76. A novel PSEN1 H163P mutation in a patient with early-onset Alzheimer's disease: clinical, neuroimaging, and neuropathological findings. Kim J, Bagyinszky E, Chang YH, Choe G, Choi B-O, An SSA, Kim S, Neurosci Lett 2012 530 109 114 10.1016/j.neulet.2012.09.040 23046926
77. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE, Hurt EM, Stem Cells Transl Med 2013 2 43 52 10.5966/sctm.2012-0036 23283488
78. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC, Cancer Res 2012 72 3091 3104 10.1158/0008-5472.CAN-11-3546 22505648
79. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker. Lee HW, Choe M, Pathol Int 2012 62 735 741 10.1111/pin.12001 23121604
80. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Banerjee R, Mani R-S, Russo N, Scanlon CS, Tsodikov A, Jing X, Cao Q, Palanisamy N, Metwally T, Inglehart RC, Tomlins S, Bradford C, Carey T, Wolf G, Kalyana-Sundaram S, Chinnaiyan AM, Varambally S, D'Silva NJ, Oncogene 2011 30 4339 4349 10.1038/onc.2011.141 21532618
81. Cytotoxicity of 5-Aza-2'-deoxycytidine against gastric cancer involves DNA damage in an ATM-P53 dependent signaling pathway and demethylation of P16(INK4A). Liu J, Xie Y-S, Wang F-L, Zhang L-J, Zhang Y, Luo H-S, Biomed Pharmacother Biomédecine Pharmacothérapie 2013 67 78 87 23201008